New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
12:18 EDTMYL, NDZ, MNTA, PRAN, MU, TEVA, TOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday in the last trading day of the first quarter of the year. The disappointing Chicago purchasing managers' report was offset by dovish comments from Fed Chief Yellen, who said the the central bank’s "extraordinary" aid will last for "some time.” ECONOMIC EVENTS: In the U.S., the Chicago PMI business barometer index came in at 55.9, versus the consensus forecast for a 59.0 reading. In Europe, the annual inflation rate across the 18-country eurozone fell for the third consecutive month, slipping to 0.5% in March, compared to analysts' consensus forecast for a milder drop to 0.6%. COMPANY NEWS: Shares of AT&T (T) advanced early in the session after the company's board of directors authorized the repurchase of up to 300M shares, or about 6% of its common shares outstanding. The company also noted it has 125M shares left under its buyback authorization that was issued in March of last year, but the stock had given up much of its early advance to be up fractionally near noon. MAJOR MOVERS: Among the notable gainers was Canada's Nordion (NDZ), which jumped 11% after the company agreed to be acquired by Sterigenics for $11.75 per share in cash shortly after Canada's government lifted its 25% limit on foreign investment in the company. Also higher following analyst commentary was Micron (MU), which rose nearly 8% amid notes in its defense from Stifel and Pacific Crest, as well as broad-based strength in technology stocks that have recently pulled back. Among the noteworthy losers were Momenta Pharmaceuticals (MNTA), which dropped 15%, and Mylan (MYL), which slipped over 1%, after the Supreme Court agreed to hear an appeal by Teva (TEVA) of a court ruling that would enable generic versions of its multiple sclerosis drug, Copaxone, to be sold in May. Also lower were shares of Prana Biotechnology (PRAN), which plunged over 70% after its clinical study of a drug being tested as a treatment of Alzheimer's Disease did not hit its primary endpoint. INDEXES: Near midday, the Dow was up 118.43, or 0.73%, to 16,441.49, the Nasdaq was up 52.48, or 1.26%, to 4,208.23, and the S&P 500 was up 14.56, or 0.78%, to 1,872.18.
News For T;PRAN;NDZ;TEVA;MNTA;MYL;MU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
June 25, 2015
07:44 EDTMUMicron volatility elevated into Q3 and outlook
Subscribe for More Information
06:44 EDTTAT&T upgraded to Buy from Neutral at BofA/Merrill
June 24, 2015
17:57 EDTMUWall Street applauds Senate giving go-ahead for 'fast track' trade powers
Subscribe for More Information
16:00 EDTMU, TActionable Options for Wednesday, June, 24
iPath S&P 500 VIX Short-Term Futures up 30c to 17.32 Option volume leaders: AAPL FB NFLX BAC VALE MU BABA WMB T F EBAY FCX TWTR BBRY
09:35 EDTT, MUActive equity options trading on open
Subscribe for More Information
09:22 EDTMUMicron shares look 'egregiously inexpensive,' says Needham
Subscribe for More Information
08:04 EDTTEVATeva launches PainMatters.com to support ‘responsible pain management’
Subscribe for More Information
07:43 EDTMUMicron June weekly volatility increases into Q3 and outlook
Micron June weekly option implied volatility is at 87, July is at 42, October is at 36; compared to its 52-range of 28 to 61, suggesting large near term price movement into its expected release of Q3 results on June 25.
07:30 EDTMUMicron fundamentals at inflection point, says UBS
UBS believes that Micron Technology fundamentals are at an inflection point and recommends buying the shares at current levels. The firm expects Q3 results and guidance can be better than feared and sees an earnings recovery, mostly influenced by smartphone fundamentals given significantly higher DRAM content. UBS maintained its $35 price target on Micron shares.
06:09 EDTMUOptions expected to be active
Options expected to be active: NFLX SYY MU MON NKE BBBY LEN NBG GREK
June 23, 2015
19:31 EDTTT-Mobile petitions FCC to deny certain AT&T spectrum licenses
Subscribe for More Information
16:00 EDTT, MUOptions Update; June 23, 2015
iPath S&P 500 VIX Short-Term Futures down 46c to 17. Option volume leaders: AAPL FB AAPL T BAC MU BTU WMB AMZN TWTR BBRY
14:16 EDTMYL, TEVABMO Capital sees strong fundamentals in Perrigo regardless of Mylan deal
Shares of Perrigo (PRGO) are trading higher intraday after BMO Capital Markets initiated coverage of the stock with an Outperform rating. The research firm is bullish on the shares regardless of whether Mylan's bid for the company succeeds, saying Perrigo is well-positioned to ride momentum in reduced-price healthcare. WHAT'S NEW: BMO Capital Markets' David Maris initiated coverage of Perrigo with an Outperform rating and a $246 price target. Maris cited the company's 70%-plus market share in store- and private-label brands, as well as its roughly $1B annual sales in the generics space. The analyst believes Perrigo will see continued benefit from larger trends driving consumer-centric healthcare and the curtailing of medical costs. WHAT'S NOTABLE: BMO Capital Markets noted that two upcoming Tysabri-related events are not accounted for by the Street, giving rise to a "significant" undervaluing of the shares. Mylan (MYL) has submitted multiple unsolicited offers for Perrigo, and while the likelihood of the deal seems low given Perrigo's numerous rejections and Teva's (TEVA) 4.61% blocking stake in Mylan. BMO Capital remarked that a failed deal should see "limited downside" for Perrigo. There could certainly be near-term volatility if a Mylan agreement doesn't materialize, but the analyst was confident in the well-positioned company's ability to deliver on both earnings per share and cash flow. PRICE ACTION: Shares of Perrigo are up nearly 2% in afternoon trading. The company saw a nearly 25% leap following Mylan's initial offer on April 8, though it has since dipped from that high.
11:39 EDTMUStocks with call strike movement; TSLA MU
Subscribe for More Information
10:00 EDTTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:36 EDTT, MUActive equity options trading on open
Subscribe for More Information
08:49 EDTTEVA, MYLMylan CFO to meet with Tel Aviv bourse head Wednesday, Reuters says
Subscribe for More Information
06:01 EDTMYLPerrigo initiated with an Outperform at BMO Capital
BMO Capital analyst David Maris started Perrigo (PRGO) with an Outperform rating and $246 price target. Maris calls shares "significantly undervalued" on a fundamental basis and sees limited downside risk should Mylan (MYL) remove its unsolicited bid for the company.
05:41 EDTTAT&T upgraded to Buy from Neutral at UBS
UBS analyst John Hodulik upgraded AT&T (T) to Buy citing an attractive valuation at current share levels. Hodulik expects the phone giant's core domestic wireless business to show "meaningful improvement" in Q2. He also thinks financial benefits from the DirecTV (DTV) acquisition are being underappreciated by the market. Hodulik raised his price target for AT&T shares to $42 from $34. The stock was also upgraded this morning by Barclays analyst Amir Rozwadowski. AT&T shares closed yesterday up 5c to $35.04.
05:35 EDTTAT&T upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Amir Rozwadowski upgraded AT&T (T) to Overweight saying earnings estimates should move higher following the close of the DirecTV (DTV) acquisition. After visiting AT&T's headquarters, Rozwadowski believes synergies from the deal are "too material to ignore." He raised his price target for AT&T shares to $39 from $34. The stock closed yesterday up 5c to $35.04.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use